Orbifloxacin

DB11443

small molecule vet_approved

Deskripsi

Orbifloxacin is a fluoroquinolone antibiotic. It is marketed by Schering-Plough Animal Health and approved for certain infections in dogs.

Struktur Molekul 2D

Berat 395.382
Wujud -

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

935 Data
Didanosine Didanosine can cause a decrease in the absorption of Orbifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Probenecid Probenecid may decrease the excretion rate of Orbifloxacin which could result in a higher serum level.
Quinapril Quinapril can cause a decrease in the absorption of Orbifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Calcium acetate Calcium acetate can cause a decrease in the absorption of Orbifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Sevelamer Sevelamer can cause a decrease in the absorption of Orbifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Iron Dextran Iron Dextran can cause a decrease in the absorption of Orbifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Calcium Calcium can cause a decrease in the absorption of Orbifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Calcium carbonate Calcium carbonate can cause a decrease in the absorption of Orbifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Lanthanum carbonate Lanthanum carbonate can cause a decrease in the absorption of Orbifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Ferric carboxymaltose Ferric carboxymaltose can cause a decrease in the absorption of Orbifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Iron sucrose Iron sucrose can cause a decrease in the absorption of Orbifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Ferric pyrophosphate Ferric pyrophosphate can cause a decrease in the absorption of Orbifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Calcium citrate Calcium citrate can cause a decrease in the absorption of Orbifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Calcium gluconate Calcium gluconate can cause a decrease in the absorption of Orbifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Ferric sulfate Ferric sulfate can cause a decrease in the absorption of Orbifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Ferric cation Ferric cation can cause a decrease in the absorption of Orbifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Tetraferric tricitrate decahydrate Tetraferric tricitrate decahydrate can cause a decrease in the absorption of Orbifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Lanthanum III cation Lanthanum III cation can cause a decrease in the absorption of Orbifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Calcium polycarbophil Calcium polycarbophil can cause a decrease in the absorption of Orbifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Ferric oxyhydroxide Ferric oxyhydroxide can cause a decrease in the absorption of Orbifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Sucralfate Sucralfate can cause a decrease in the absorption of Orbifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Zolmitriptan The metabolism of Zolmitriptan can be decreased when combined with Orbifloxacin.
Nitrofurantoin The therapeutic efficacy of Orbifloxacin can be decreased when used in combination with Nitrofurantoin.
Mycophenolate mofetil The serum concentration of Mycophenolate mofetil can be decreased when it is combined with Orbifloxacin.
Mycophenolic acid The serum concentration of Mycophenolic acid can be decreased when it is combined with Orbifloxacin.
Picosulfuric acid The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Orbifloxacin.
Insulin human The therapeutic efficacy of Insulin human can be increased when used in combination with Orbifloxacin.
Insulin lispro The therapeutic efficacy of Insulin lispro can be increased when used in combination with Orbifloxacin.
Insulin pork The therapeutic efficacy of Insulin pork can be increased when used in combination with Orbifloxacin.
Troglitazone The therapeutic efficacy of Troglitazone can be increased when used in combination with Orbifloxacin.
Glimepiride The therapeutic efficacy of Glimepiride can be increased when used in combination with Orbifloxacin.
Sulfisoxazole The therapeutic efficacy of Sulfisoxazole can be increased when used in combination with Orbifloxacin.
Acarbose The therapeutic efficacy of Acarbose can be increased when used in combination with Orbifloxacin.
Metformin The therapeutic efficacy of Metformin can be increased when used in combination with Orbifloxacin.
Sulfadiazine The therapeutic efficacy of Sulfadiazine can be increased when used in combination with Orbifloxacin.
Rosiglitazone The therapeutic efficacy of Rosiglitazone can be increased when used in combination with Orbifloxacin.
Acetohexamide The therapeutic efficacy of Acetohexamide can be increased when used in combination with Orbifloxacin.
Miglitol The therapeutic efficacy of Miglitol can be increased when used in combination with Orbifloxacin.
Chlorpropamide The therapeutic efficacy of Chlorpropamide can be increased when used in combination with Orbifloxacin.
Nateglinide The therapeutic efficacy of Nateglinide can be increased when used in combination with Orbifloxacin.
Pentamidine The therapeutic efficacy of Pentamidine can be increased when used in combination with Orbifloxacin.
Tolazamide The therapeutic efficacy of Tolazamide can be increased when used in combination with Orbifloxacin.
Repaglinide The therapeutic efficacy of Repaglinide can be increased when used in combination with Orbifloxacin.
Phenformin The therapeutic efficacy of Phenformin can be increased when used in combination with Orbifloxacin.
Sulfamethoxazole The therapeutic efficacy of Sulfamethoxazole can be increased when used in combination with Orbifloxacin.
Glyburide The therapeutic efficacy of Glyburide can be increased when used in combination with Orbifloxacin.
Glipizide The therapeutic efficacy of Glipizide can be increased when used in combination with Orbifloxacin.
Gliclazide The therapeutic efficacy of Gliclazide can be increased when used in combination with Orbifloxacin.
Tolbutamide The therapeutic efficacy of Tolbutamide can be increased when used in combination with Orbifloxacin.
Pioglitazone The therapeutic efficacy of Pioglitazone can be increased when used in combination with Orbifloxacin.
Bromocriptine The therapeutic efficacy of Bromocriptine can be increased when used in combination with Orbifloxacin.
Gliquidone The therapeutic efficacy of Gliquidone can be increased when used in combination with Orbifloxacin.
Mitiglinide The therapeutic efficacy of Mitiglinide can be increased when used in combination with Orbifloxacin.
Sitagliptin The therapeutic efficacy of Sitagliptin can be increased when used in combination with Orbifloxacin.
Sunitinib The therapeutic efficacy of Sunitinib can be increased when used in combination with Orbifloxacin.
Exenatide The therapeutic efficacy of Exenatide can be increased when used in combination with Orbifloxacin.
Mecasermin The therapeutic efficacy of Mecasermin can be increased when used in combination with Orbifloxacin.
Pramlintide The therapeutic efficacy of Pramlintide can be increased when used in combination with Orbifloxacin.
Glisoxepide The therapeutic efficacy of Glisoxepide can be increased when used in combination with Orbifloxacin.
Insulin aspart The therapeutic efficacy of Insulin aspart can be increased when used in combination with Orbifloxacin.
Insulin glulisine The therapeutic efficacy of Insulin glulisine can be increased when used in combination with Orbifloxacin.
Glymidine The therapeutic efficacy of Glymidine can be increased when used in combination with Orbifloxacin.
AICA ribonucleotide The therapeutic efficacy of AICA ribonucleotide can be increased when used in combination with Orbifloxacin.
Buformin The therapeutic efficacy of Buformin can be increased when used in combination with Orbifloxacin.
Vildagliptin The therapeutic efficacy of Vildagliptin can be increased when used in combination with Orbifloxacin.
Voglibose The therapeutic efficacy of Voglibose can be increased when used in combination with Orbifloxacin.
NN344 The therapeutic efficacy of NN344 can be increased when used in combination with Orbifloxacin.
AMG-222 The therapeutic efficacy of AMG-222 can be increased when used in combination with Orbifloxacin.
Bisegliptin The therapeutic efficacy of Bisegliptin can be increased when used in combination with Orbifloxacin.
Alogliptin The therapeutic efficacy of Alogliptin can be increased when used in combination with Orbifloxacin.
Dapagliflozin The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Orbifloxacin.
Saxagliptin The therapeutic efficacy of Saxagliptin can be increased when used in combination with Orbifloxacin.
Liraglutide The therapeutic efficacy of Liraglutide can be increased when used in combination with Orbifloxacin.
Gosogliptin The therapeutic efficacy of Gosogliptin can be increased when used in combination with Orbifloxacin.
Linagliptin The therapeutic efficacy of Linagliptin can be increased when used in combination with Orbifloxacin.
Canagliflozin The therapeutic efficacy of Canagliflozin can be increased when used in combination with Orbifloxacin.
Glibornuride The therapeutic efficacy of Glibornuride can be increased when used in combination with Orbifloxacin.
Benfluorex The therapeutic efficacy of Benfluorex can be increased when used in combination with Orbifloxacin.
Empagliflozin The therapeutic efficacy of Empagliflozin can be increased when used in combination with Orbifloxacin.
Albiglutide The therapeutic efficacy of Albiglutide can be increased when used in combination with Orbifloxacin.
Dulaglutide The therapeutic efficacy of Dulaglutide can be increased when used in combination with Orbifloxacin.
Lobeglitazone The therapeutic efficacy of Lobeglitazone can be increased when used in combination with Orbifloxacin.
Netoglitazone The therapeutic efficacy of Netoglitazone can be increased when used in combination with Orbifloxacin.
Rivoglitazone The therapeutic efficacy of Rivoglitazone can be increased when used in combination with Orbifloxacin.
Ciglitazone The therapeutic efficacy of Ciglitazone can be increased when used in combination with Orbifloxacin.
Lixisenatide The therapeutic efficacy of Lixisenatide can be increased when used in combination with Orbifloxacin.
Insulin beef The therapeutic efficacy of Insulin beef can be increased when used in combination with Orbifloxacin.
Insulin degludec The therapeutic efficacy of Insulin degludec can be increased when used in combination with Orbifloxacin.
Insulin peglispro The therapeutic efficacy of Insulin peglispro can be increased when used in combination with Orbifloxacin.
Insulin tregopil The therapeutic efficacy of Insulin tregopil can be increased when used in combination with Orbifloxacin.
Ipragliflozin The therapeutic efficacy of Ipragliflozin can be increased when used in combination with Orbifloxacin.
Dutogliptin The therapeutic efficacy of Dutogliptin can be increased when used in combination with Orbifloxacin.
Allicin The therapeutic efficacy of Allicin can be increased when used in combination with Orbifloxacin.
Tofogliflozin The therapeutic efficacy of Tofogliflozin can be increased when used in combination with Orbifloxacin.
Ertugliflozin The therapeutic efficacy of Ertugliflozin can be increased when used in combination with Orbifloxacin.
2,4-thiazolidinedione The therapeutic efficacy of 2,4-thiazolidinedione can be increased when used in combination with Orbifloxacin.
Teneligliptin The therapeutic efficacy of Teneligliptin can be increased when used in combination with Orbifloxacin.
Omarigliptin The therapeutic efficacy of Omarigliptin can be increased when used in combination with Orbifloxacin.
Carmegliptin The therapeutic efficacy of Carmegliptin can be increased when used in combination with Orbifloxacin.
Gemigliptin The therapeutic efficacy of Gemigliptin can be increased when used in combination with Orbifloxacin.

Referensi & Sumber

Artikel (PubMed)
  • PMID: 22433170
    Harada K, Shimizu T, Kataoka Y, Takahashi T: Post-antibiotic effect of orbifloxacin against Escherichia coli and Pseudomonas aeruginosa isolates from dogs. Acta Vet Scand. 2012 Mar 20;54:16. doi: 10.1186/1751-0147-54-16.
  • PMID: 11480524
    Haines GR, Brown MP, Gronwall RR, Merritt KA, Baltzley LK: Pharmacokinetics of orbifloxacin and its concentration in body fluids and in endometrial tissues of mares. Can J Vet Res. 2001 Jul;65(3):181-7.
  • PMID: 18958455
    Llorent-Martinez EJ, Ortega-Barrales P, Molina-Diaz A, Ruiz-Medina A: Implementation of terbium-sensitized luminescence in sequential-injection analysis for automatic analysis of orbifloxacin. Anal Bioanal Chem. 2008 Dec;392(7-8):1397-403. doi: 10.1007/s00216-008-2434-9. Epub 2008 Oct 29.
  • PMID: 9118451
    Morimura T, Nobuhara Y, Matsukura H: Photodegradation products of a new antibacterial fluoroquinolone derivative, orbifloxacin, in aqueous solution. Chem Pharm Bull (Tokyo). 1997 Feb;45(2):373-7.
  • PMID: 7641301
    Morimura T, Ohno T, Matsukura H, Nobuhara Y: Photodegradation kinetics of the new antibacterial fluoroquinolone derivative, orbifloxacin, in aqueous solution. Chem Pharm Bull (Tokyo). 1995 Jun;43(6):1000-4.
  • PMID: 16237956
    Szczypka M, Gaweda B, Obminska-Mrukowicz B: Modulation of cellular immune response by orbifloxacin in noninfected and E. coli-infected mice. Immunopharmacol Immunotoxicol. 2005;27(3):461-72.
  • PMID: 16669863
    Davis JL, Papich MG, Weingarten A: The pharmacokinetics of orbifloxacin in the horse following oral and intravenous administration. J Vet Pharmacol Ther. 2006 Jun;29(3):191-7.
  • PMID: 21233597
    Gebru E, Lee SJ, Kim JC, Park SC: Allometric scaling of orbifloxacin disposition in nine mammal species: a retrospective analysis. J Vet Med Sci. 2011 Jun;73(6):817-20. Epub 2011 Jan 12.
Menampilkan 8 dari 9 artikel.

Contoh Produk & Brand

Produk: 0 • International brands: 1
International Brands
  • Orbax

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul